In a nutshell This study is examining the effects of IGM-2323 for certain types of relapsed/unresponsive non-Hodgkin lymphoma. The main outcomes that will be measured are the side effects experienced by patients and the effectiveness of treatment. This trial is recruiting in the United States. The details Non-Hodgkin lymphoma (NHL) is a...
Read MoreType of non Hodgkin’s lymphoma-Follicular lymphoma Posts on Medivizor
Lymphoma transformation risk in patients with advanced follicular lymphoma
In a nutshell This study investigated the frequency of lymphoma transformation in patients with advanced-stage follicular lymphoma (FL) after treatment with BR (bendamustine, rituximab). This study concluded these patients might be at risk for lymphoma transformation after initial treatment. Some background FL is the second most common type of...
Read MoreSurviving cancer – is there a greater risk of cardiovascular disease long-term?
In a nutshell This study investigated if there is a higher risk of cardiovascular disease (CVD) in cancer survivors. They found that cancer survivors have a higher risk of CVD. Some background Improved cancer detection and treatment has increased the rates of survival. The number of cancer survivors living for more than 10 years is growing. Some...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreFertility options for female patients with lymphoma or leukemia
In a nutshell This article reviewed different options to preserve or restore fertility in female patients with lymphoma or leukemia. Some background Impaired reproductive function is one possible side effect of aggressive chemotherapy and radiotherapy for cancer. In severe cases, intensive anti-cancer treatment can lead to fertility loss. 7 to 9% of...
Read MoreEvaluating the risk of secondary cancers from infections in patients with non-Hodgkin’s lymphoma
In a nutshell This study examined whether there is a link between the type of non-Hodgkin’s lymphoma (NHL) and the development of secondary cancer due to certain infections. The authors concluded that patients with diffuse large B-cell lymphoma (DLBCL) or marginal zone lymphoma (MZL) may be at risk for developing a second type of...
Read MoreTreatment guidelines for patients with B-cell lymphomas
In a nutshell This article provided guidelines for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Some background DLBCL and FL are the most common types of non-Hodgkin’s lymphoma in adults. FL has the potential to transform into a more aggressive type of lymphoma. The most common transformation...
Read MoreEvaluating SCR chemotherapy for patients with non-Hodgkin’s lymphoma
In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...
Read MoreSecond primary cancers in patients with non-Hodgkin lymphoma
In a nutshell This study aimed to investigate second primary cancers in patients with non-Hodgkin lymphoma. This study concluded that family history influenced second primary cancers and that second primary cancers influenced survival. Some background Non Hodgkin lymphoma (NHL) survival has improved greatly. There has been an increased...
Read MoreVenetoclax treatment regimes in non-Hodgkin lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of two venetoclax (Venclexta) treatment regimes in non-Hodgkin lymphoma patients. This study concluded that one of these regimes was safe and showed effectiveness in these patients. The recommended dose of venetoclax was also found. Some background New therapies...
Read MoreCombination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients with NHL are often treated with targeted therapies....
Read MoreCombination of ublituximab, umbralisib and ibrutinib for patients with leukemia and lymphoma
In a nutshell This study aimed to investigate the safety and effectiveness of ublituximab, umbralisib and ibrutinib combination in patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). This study concluded that this combination appears safe and effective for these patients. Some background Patients...
Read More
